1. Home
  2. SNGX vs TPST Comparison

SNGX vs TPST Comparison

Compare SNGX & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Soligenix Inc.

SNGX

Soligenix Inc.

HOLD

Current Price

$1.39

Market Cap

14.4M

Sector

Health Care

ML Signal

HOLD

Logo Tempest Therapeutics Inc.

TPST

Tempest Therapeutics Inc.

HOLD

Current Price

$2.91

Market Cap

15.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SNGX
TPST
Founded
1987
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.4M
15.1M
IPO Year
1987
N/A

Fundamental Metrics

Financial Performance
Metric
SNGX
TPST
Price
$1.39
$2.91
Analyst Decision
Strong Buy
Buy
Analyst Count
1
2
Target Price
$6.00
$10.00
AVG Volume (30 Days)
195.6K
87.9K
Earning Date
11-07-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.09
$2.40
52 Week High
$6.23
$13.13

Technical Indicators

Market Signals
Indicator
SNGX
TPST
Relative Strength Index (RSI) 47.26 44.10
Support Level $1.35 $2.56
Resistance Level $1.46 $3.15
Average True Range (ATR) 0.08 0.19
MACD 0.01 0.12
Stochastic Oscillator 31.25 69.85

Price Performance

Historical Comparison
SNGX
TPST

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

About TPST Tempest Therapeutics Inc.

Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.

Share on Social Networks: